Impact of clinical pathway on the treatment outcome in patients with Crohn’s disease complicated with intra-abdominal abscesses

曹磊,李毅,龚剑峰,郭振,丁成亮,顾立立,韦瑶,苏化,朱维铭,黎介寿
DOI: https://doi.org/10.7504/CJPS.ISSN1005-2208.2016.11.19
2016-01-01
Abstract:Objective To evaluate the effect of a clinical pathway on treatment outcomes in patients with Crohn’s disease(CD)complicated with intra-abdominal abscesses. Methods The clinical data of 30 CD patients with intra-abdominal abscesses admitted from January 2014 to December 2014 in Inflammatory Bowel Disease Treatment Center of Nanjing General Hospital of Nanjing Military Area Command ( clinical pathway group ) were analyzed retrospectively. Meanwhile, 30 patients according to the implementation of the designed clinical pathway between January 2013 and December 2013 were non-pathway group. The treatment outcomes between the two groups were compared. Results All patients were cured in both groups. The completion rate of the clinical pathway used was 100%. No difference was noted in terms of the rate of surgery[80.0%(24/30) vs. 66.7%(20/30)],postoperative complications [29.2%(7/24) vs. 50.0%(10/20)] and hospital cost[(56 745 ± 45 465)yuan vs. (73 928 ± 50 576)yuan]. However, compared with non-pathway group,the rate of temporary stoma was lower in pathway group[16.7%(4/24) vs. 55.0%(11/20),P=0.011],and the LOS was shorter[(28.9 ± 21.4)d vs. (43.8 ± 34.3)d,P=0.047]. In addition,during the one year of follow-up period,there was no meaningful difference in the recurrence of abscesses between the two groups (P=1.000). Conclusion Clinical pathway may decrease the intestinal stoma rate and LOS in CD patients complicated with intra-abdominal abscesses.
What problem does this paper attempt to address?